BioCentury
ARTICLE | Clinical News

Edarbyclor azilsartan medoxomil/chlorthalidone regulatory update

January 2, 2012 8:00 AM UTC

FDA approved an NDA from Takeda for Edarbyclor azilsartan/chlorthalidone to treat hypertension. The product is a fixed-dose combination of azilsartan, an angiotensin II type 1 (AT1) receptor blocker,...